Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody

Blood. 2001 Apr 15;97(8):2527-8. doi: 10.1182/blood.v97.8.2527.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD20 / immunology*
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Disease Progression
  • Humans
  • Immunization, Passive
  • Immunoglobulin M / blood
  • Immunoglobulin kappa-Chains / blood
  • Male
  • Monoclonal Gammopathy of Undetermined Significance / drug therapy
  • Monoclonal Gammopathy of Undetermined Significance / metabolism
  • Monoclonal Gammopathy of Undetermined Significance / therapy*
  • Myeloproliferative Disorders / chemically induced*
  • Paraproteins / analysis
  • Thalidomide / adverse effects*
  • Thalidomide / therapeutic use
  • Thrombocytosis / chemically induced*
  • Waldenstrom Macroglobulinemia / etiology*

Substances

  • Antibodies, Monoclonal
  • Antigens, CD20
  • Antineoplastic Agents
  • Immunoglobulin M
  • Immunoglobulin kappa-Chains
  • Paraproteins
  • Thalidomide